US4755385A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin
Assignee: Boehringer Ingelheim Pharma GmbH and Co KG
•
Filing: 1986-07-08
•
Granted: 1988-07-05
•
Expires: 2006-07-08
Abstract
Abstract There is described a solid pharmaceutical preparation for oral administration which produces high and long-lasting blood and tissue levels, containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]oxy]-(9S)- erythromycin as active substance, in which the active substance must be intimately mixed with a basic excipient in a ratio of 1 mol of active substance to at least 2 gram-equivalents of basic excipient, and the preparations are coated with a gastric juice-resistant lacquer which is soluble in a pH range of between 5.5 and 6.8, and processes for preparing them. The solid pharmaceutical preparations include tablets, pellets or granules and a syrup can be produced from the latter.
Inventors
- 👤 Alain Etienne
- 👤 Peter Gruber
- 👤 Ulrich Busch
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 03:29
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7042; A61K31/7048; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1611; A61K9/1617; A61K9/20; A61K9/2004; A61K9/2009; A61K9/28; A61K9/2806; A61K9/2833; A61K9/284; A61K9/2846; A61K9/286; A61K9/2866; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/5036; A61K9/5042; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
82 words
A solid pharmaceutical preparation for oral administration comprising 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin intimately mixed with a basic excipient in a ratio of 1 mol of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin to at least 2 gram-equivalents of basic excipient and an effective amount of a disintegrant, to insure disintegration, fast resorption and action, and coated with a gastric juice-resistant lacquer which releases the 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin for resorption in the uppermost sections of the intestines, where blood levels are achieved, other than the colon, in a pH range between 5.5 and 6.8.
Claim 2
Dependent Claim
82 words
A solid pharmaceutical preparation for oral administration comprising 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin intimately mixed with a basic excipient in a ratio of 1 mol of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin to at least 2 gram-equivalents of basic excipient and an effective amount of a disintegrant, to insure disintegration, fast resorption and action, and coated with a gastric juice-resistant lacquer which releases the 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin for resorption in the uppermost sections of the intestines, where blood levels are achieved, other than the colon, in a pH range between 5.5 and 6.8.
Claim 3
Dependent Claim
34 words
The solid pharmaceutical preparation of claim 1, in which the intimate mixture of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin, said basic excipient and said disintegrant is compressed to form a tablet which is coated with said gastric juice-resistant lacquer.
Claim 4
Dependent Claim
34 words
The solid pharmaceutical preparation of claim 1 in which the intimate mixture of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]oxy]-(9S)-erythromycin, said basic excipient and said disintegrant is present in pellet form, which pellets are coated with said gastric juice-resistant lacquer.
Claim 5
Dependent Claim
34 words
The solid pharmaceutical preparation of claim 1 in which the intimate mixture of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin, said basic excipient and said disintegrant is present in granulate form which granules are coated with said gastric juice-resistant lacquer.
Claim 6
Dependent Claim
38 words
The solid pharmaceutical preparation of claim 1 in which the intimate mixture of 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin, said basic excipient and said disintegrant is present in the form of spray-hardened spheroid particles, which particles are coated with said gastric juice-resistant lacquer.
Claim 7
Dependent Claim
26 words
The solid pharmaceutical preparation of claim 1 in which the gastric juice-resistant lacquer which releases the 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin in a pH range of between 6.0 and 6.4.
Claim 8
Dependent Claim
50 words
The solid pharmaceutical preparation of claim 1 in which said basic excipient is magnesium oxide, magnesium carbonate, magnesium hydrogen carbonate, magnesium hydroxide, calcium hydroxide, calcium carbonate, magnesium aluminium hydroxide, magnesium aluminate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, sodium hydroxide, postassium hydroxide, trisodium phosphate, or mixtures thereof.
References Cited (Backward Citations)
US3081233A
Cited
US3784683A
Cited
US3865935A
Cited
US3891755A
Cited
US4127647A
Cited
US4101651A
Cited
US4289751A
Cited
US4340582A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-05 | 1992-01-04 | 1992-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-05 | 1996-01-04 | 1996-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-05 | 2000-01-04 | 2000-07-05 | $7700.00 | Window Closed / Lapsed |